9,978 Shares in Haemonetics Corp. (HAE) Acquired by Mason Street Advisors LLC
Mason Street Advisors LLC acquired a new stake in shares of Haemonetics Corp. (NYSE:HAE) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 9,978 shares of the company’s stock, valued at approximately $289,000.
Other large investors have also recently bought and sold shares of the company. Rutabaga Capital Management LLC MA purchased a new stake in Haemonetics Corp. during the second quarter valued at $17,805,000. Fuller & Thaler Asset Management Inc. increased its stake in Haemonetics Corp. by 17.1% in the second quarter. Fuller & Thaler Asset Management Inc. now owns 2,134,641 shares of the company’s stock valued at $61,883,000 after buying an additional 311,959 shares during the last quarter. Heartland Advisors Inc. purchased a new stake in Haemonetics Corp. during the second quarter valued at $7,498,000. Dimensional Fund Advisors LP increased its stake in Haemonetics Corp. by 14.5% in the second quarter. Dimensional Fund Advisors LP now owns 1,804,922 shares of the company’s stock valued at $52,324,000 after buying an additional 228,856 shares during the last quarter. Finally, Van Berkom & Associates Inc. increased its stake in Haemonetics Corp. by 17.3% in the second quarter. Van Berkom & Associates Inc. now owns 1,526,725 shares of the company’s stock valued at $44,260,000 after buying an additional 224,655 shares during the last quarter. 98.64% of the stock is owned by institutional investors and hedge funds.
Haemonetics Corp. (NYSE:HAE) opened at 36.55 on Friday. The stock’s market cap is $1.87 billion. Haemonetics Corp. has a 52-week low of $25.98 and a 52-week high of $38.06. The firm has a 50-day moving average price of $36.77 and a 200 day moving average price of $32.51.
Haemonetics Corp. (NYSE:HAE) last posted its quarterly earnings data on Monday, August 1st. The company reported $0.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by $0.03. The business had revenue of $210 million for the quarter, compared to analysts’ expectations of $205.41 million. Haemonetics Corp. had a positive return on equity of 10.75% and a negative net margin of 7.25%. Haemonetics Corp.’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.35 earnings per share. Equities analysts anticipate that Haemonetics Corp. will post $1.44 earnings per share for the current year.
HAE has been the subject of several research analyst reports. Sidoti downgraded Haemonetics Corp. from a “buy” rating to a “neutral” rating and set a $39.00 price objective for the company. in a report on Monday, August 15th. Benchmark Co. increased their price objective on Haemonetics Corp. from $28.00 to $32.00 and gave the company a “hold” rating in a report on Tuesday, August 2nd. CJS Securities downgraded Haemonetics Corp. from a “market outperform” rating to a “market perform” rating and set a $35.00 price objective for the company. in a report on Tuesday, September 20th. Zacks Investment Research upgraded Haemonetics Corp. from a “strong sell” rating to a “hold” rating in a research note on Monday, July 4th. Finally, Jefferies Group upped their price target on Haemonetics Corp. from $32.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company’s stock. Haemonetics Corp. has an average rating of “Hold” and a consensus target price of $34.50.
In other news, CEO Christopher Simon bought 60,000 shares of the firm’s stock in a transaction dated Thursday, August 4th. The stock was bought at an average price of $35.00 per share, for a total transaction of $2,100,000.00. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Ronald Merriman sold 4,337 shares of Haemonetics Corp. stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $35.14, for a total value of $152,402.18. Following the completion of the transaction, the director now owns 22,088 shares of the company’s stock, valued at approximately $776,172.32. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.
About Haemonetics Corp.
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corp. (NYSE:HAE).
Receive News & Ratings for Haemonetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.